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1 Introduction 
The Swiss Childhood Cancer Registry (SCCR) is the national population-based 
cancer registry for children in Switzerland. Since 1976, it registers new cancer 
diagnoses, clinical information, details on treatment and long term follow-up (survival, 
second tumours and late effects). With many associated research projects and through 
close collaboration with clinicians it contributes to understanding the causes of cancer in 
children, improving treatment and follow-up care and reducing late effects. 
The SCCR is located at the Institute of Social and Preventive Medicine (ISPM) at the 
University of Bern and closely cooperates with the Swiss Paediatric Oncology Group 
(SPOG) and the National Institute for Cancer Epidemiology and Registration (NICER). 
All Swiss paediatric haematology-oncology centres report newly diagnosed cases to the 
registry and send annual updates on clinical follow-up afterwards. Since 2007, the 
SCCR systematically collects data from other sources such as the cantonal cancer 
registries, other hospitals, pathology laboratories and the Federal Statistical Office 
(FSO). As of 31st December 2009 data from 6099 cases have been registered.  
The Federal Commission of Experts for Professional Secrecy in Medical Research 
(Eidgenössische Expertenkommission für das Berufsgeheimnis in der medizinischen 
Forschung) gave the SCCR a general authorization for collecting non-anonymised data.  
The SCCR is an associated member of the National Institute for Cancer Epidemiology 
and Registration (NICER), of the European Network of Cancer Registries (ENCR) and 
of the International Association of Cancer Registries (IACR). It collaborates with 
childhood cancer registries throughout Europe, e.g. the German Childhood Cancer 
Registry in Mainz (GCCR) and the National Registry of Childhood Tumours UK in 
Oxford (NRCT). 
This 4th annual report covers the routine analyses of all children diagnosed between 
1st January 1976 and 31st December 2009. Data on children diagnosed in 2010 will be 
presented in the next annual report. Activities and projects of the SCCR are described 
for the years 2009 and 2010. In particular, this report contains: 
• an overview of the organisation and team of the SCCR, SPOG and the participating 
paediatric haematology-oncology centres (chapter 2) 
• a summary of the data collected in the registry up to 31st December 2009 (routine 
analyses; chapter 3) 
• a list of current research projects of the SCCR (chapter 4) 
• a review of activities for the years 2009 and 2010 (chapter 5) 
• a list of publications (chapter 6) 
• abbreviations and appendix (chapters 7 & 8) 
Our website (www.childhoodcancerregistry.ch) contains further information such as past 
annual reports. 
We thank all the children with their families and all the adolescent or adult childhood 
cancer survivors for allowing us to collect their data. We also thank all the physicians 
and data managers of the Swiss Paediatric Oncology Group for their excellent 
collaboration. Our thanks also go to the cantonal cancer registries, NICER, the Federal 
Statistical Office (FSO), the Federal Office of Public Health (FOPH) and the pathology 
laboratories for their cooperation. Finally, we thank all our supporters for their generous 
contributions. 
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2 Organisation of the Swiss Childhood Cancer Registry 
2.1 Team 
The Swiss Childhood Cancer Registry (SCCR) is operated jointly by the Swiss 
Paediatric Oncology Group (SPOG) and the Institute of Social and Preventive Medicine 
(ISPM) at the University of Bern. 
Institute of Social and Preventive Medicine (ISPM), University of Bern 
Finkenhubelweg 11, 3012 Bern 
Tel.: +41 (0)31 631 56 70 / +41 (0)31 631 38 99 
Fax: +41 (0)31 631 36 48 
E-Mail: kinderkrebsregister@ispm.unibe.ch 
 
Childhood cancer group 
PD Dr. med.  
Claudia Kuehni 
FMH Paediatrics,  
MSc Epidemiology 
Head of SCCR 
Overall responsibility 
kuehni@ispm.unibe.ch 
Dr. Gisela Michel, PhD Vice head of SCCR michel@ispm.unibe.ch 
Research project:  
Follow-up care after childhood and young adult cancer (CCFU) 
 
Swiss Childhood Cancer Registry 
Vera Mitter, MSc Project management vmitter@ispm.unibe.ch 
Dr. med. Elisabeth Kiraly Diagnostic coding kiraly@ispm.unibe.ch 
Marlen Spring Data management mspring@ispm.unibe.ch 
Jeannine Kropf Data management jkropf@ispm.unibe.ch 
Marianne Reck Fundraising, communication mreck@ispm.unibe.ch 
Simone Constantin Statistics sconstantin@ispm.unibe.ch 
 
Informatics and database support  
Gerrit Viehmann Logistics, database support gviehmann@ispm.unibe.ch 
Malcolm Sturdy  Database support sturdy@ispm.unibe.ch 
Philipp Läuppi Web-design, web-administration plaeuppi@ispm.unibe.ch 
 
Research projects 
Dr. med. Martin Feller Childhood Cancer and Nuclear 
Power Plants in Switzerland 
(CANUPIS) 
mfeller@ispm.unibe.ch 
Dr. med. Eva Hau PanCare SurFup ehau@ispm.unibe.ch 
Cornelia Rebholz, MSc  
Corina Rüegg, MSc 
Laura Wengenroth, MSc 
PhD students in the Swiss 
Childhood Cancer Survivor Study 
(SCCSS) 
crebholz@ispm.unibe.ch 
crueegg@ispm.unibe.ch 
lwengenroth@ispm.unibe.ch 
Marie-Pierre Strippoli, 
MSc  
Statistics, research fellow strippol@ispm.unibe.ch 
Dr. Grit Sommer, PhD 
Fatma Karabulut, MSc 
Growth Hormone project 
“SAGhE” 
gsommer@ispm.unibe.ch 
fkarabulut@ispm.unibe.ch 
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Swiss Paediatric Oncology Group (SPOG) 
 
SPOG Office  
Effingerstrasse 40, 3008 Bern 
Tel.: +41 (0)31 389 91 89  
Fax: +41 (0)31 389 92 00  
 
SPOG Executive Board   
Prof. Dr. med. Felix Niggli President felix.niggli@kispi.uzh.ch 
Dr. med. Heinz Hengartner Vice president heinz.hengartner@kispisg.ch 
PD Dr. med. Maja Beck Popovic Secretary maja.beck-popovic@chuv.ch 
PD Dr. med. Nicolas von der Weid Past president nicolas.von-der-weid@chuv.ch 
 
SPOG Office in Bern   
Isabelle Lamontagne-Müller Managing director isabelle.lamontagne@spog.ch 
Dr. Stefanie Lerch, PhD Quality assurance stefanie.lerch@spog.ch 
Martina Peluso Regulatory affairs  martina.peluso@spog.ch 
Susanna Kumli Central administration susanna.kumli@spog.ch 
 
Participating centres (haematology-oncology) 
 Head of Division Local Data Manager 
Aarau (Kinderklinik, Kantonsspital 
Aarau) 
Dr. med. R. Angst Dr. med. R. Angst 
Basel (Universitätskinderspital 
beider Basel [UKBB]) 
Prof. Dr. med. T. Kühne 
(ad interim) 
V. Stahel 
Bern (Universitätsklinik für 
Kinderheilkunde, Inselspital) 
Prof. Dr. med. K. Leibundgut F. Julmy  
N. Beusch 
Genève (Hôpital des Enfants, 
Hôpitaux Universitaires de Genève 
[HUG]) 
PD Dr. med. H. Ozsahin M. Crouche 
Lausanne (Service de Pédiatrie, 
Centre Hospitalier Universitaire 
Vaudois [CHUV]) 
PD Dr. med. M. Beck 
Popovic 
Dr. med. R.-E. Garcia 
Bellinzona (Reparto di Pediatria, 
Ospedale S. Giovanni, Bellinzona) 
Dr. med. P. Brazzola Dr. med. P. Brazzola 
Luzern (Kinderspital, Kantonsspital 
Luzern) 
PD Dr. med. J. Rischewski Y. Bonetti 
St.Gallen (Ostschweizer 
Kinderspital) 
Dr. med. J. Greiner-Lang F. Hochreutener 
Zurich (Universitäts-Kinderklinik, 
Zürich) 
Prof. Dr. med. F. Niggli 
Prof. Dr. med. M. Grotzer 
H. Markiewicz 
A. Reinberger 
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2.2 General information 
Inclusion criteria and data collection 
The SCCR registers all children and adolescents aged 0 to 20 years diagnosed with: 
• acute and chronic leukaemias, including myelodysplastic syndrome 
• lymphomas 
• solid malignancies 
• central nervous system tumours (CNS), including benign tumours 
• Langerhans cell histiocytosis (LCH) and other histiocytosis (type I–III)  
Most children are treated in, and reported by one of the nine Swiss centres for paediatric 
oncology and haematology. Additional sources of information for incident cases are 
cantonal cancer registries, the Federal Statistical Office (FSO), pathology laboratories 
and smaller hospitals. The SCCR aims for complete registration of all children and 
adolescents up to the age of 20 years. Completeness has been largely achieved for 
children aged 0-15 years at diagnosis.1 The quality of data is controlled and the date of 
death is validated against death certificates from the FSO. Children and adolescents 
who are not Swiss residents but come to Switzerland for diagnosis and treatment are 
registered, but excluded from the analyses of incidence and survival. 
Follow-up data are extracted annually from patients’ hospital records for the first 5 to 10 
years after diagnosis. When follow-up in a clinic ends, long-term follow-up is maintained 
by direct contact to the patients using a questionnaire (see chapter 4: Project 4 - Swiss 
Childhood Cancer Survivor Study) and via data linkage with mortality records (FSO) and 
cantonal cancer registries.  
In the nine paediatric haematology-oncology centres in Switzerland, local data 
managers complete forms for newly diagnosed cases, relapses, transplantations and 
clinical follow-up examinations. These forms are sent to the SCCR and information is 
entered into the database. Important medical documents (e.g. pathology reports) are 
scanned and stored electronically using a pseudonym. Paper copies are destroyed. 
Clinical database 
The currently used electronic database of the SCCR was set up in 2007. At present, the 
following information is collected: 
• tumour diagnosis, date of diagnosis, type of cancer, histology, stage, metastases 
• other diagnoses (relevant pre-existing conditions) 
• clinical information and relevant laboratory data 
• treatment (first study notification, treatment protocols, medication and dosages, 
radiotherapy, surgical interventions) 
• follow-up data (changes of treatment, remissions, relapses, survival/death and 
cause of death) 
• late effects 
• treatment centres involved 
• date of birth, sex, first language 
• parental profession(s), parental date(s) of birth 
                                               
1 Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, Probst-Hensch N, Niggli F, Kuehni CE. Access to 
specialized pediatric cancer care in Switzerland. Pediatric Blood & Cancer 2010; 54:721-7. 
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Administrative database 
Since 2010, personal information on names and addresses is collected in a separate 
database. This is an important tool to support case registration and research projects 
that need an address history from birth to the date of diagnosis, or a current address. 
The address database supports the validation of addresses, patient nationality, and vital 
status via community registration offices. The address information is kept completely 
separate from clinical information. The following data are collected:  
 
• patients’ names, address at the time of diagnosis, address history and current 
address 
• residence status and nationality at the time of diagnosis 
• vital status and date of death 
Tumour coding 
The SCCR codes all tumours according to the following international classification 
systems (see appendix):  
• International Classification of Childhood Cancer, third edition (ICCC-3)2 
• International Statistical Classification of Diseases for Oncology, third edition  
(ICD-O-3)3 
• International Statistical Classification of Diseases and Related Health Problems, 
tenth revision (ICD-10)4 
In the annual report we use the main diagnostic groups of ICCC-3:  
I. Leukaemias, II. Lymphomas, III. Central nervous system (CNS) neoplasms, 
IV. Neuroblastoma, V. Retinoblastoma, VI. Renal tumours, VII. Hepatic tumours, 
VIII. Malignant bone tumours, IX. Soft tissue sarcomas (STS), X. Germ cell tumours, 
XI. Other malignant epithelial neoplasms, XII. Other specified and unspecified malignant 
neoplasms. Langerhans cell histiocytosis (LCH), which is not contained in ICCC-3, is 
reported separately. 
Completeness  
The incidence of childhood cancers in the SCCR is comparable to the published 
incidence in Swiss cantonal cancer registries and in neighbouring countries (France, 
Germany and Italy).5 In 2006-2008, we compared the SCCR data with datasets from the 
cantonal cancer registries (Basel, Geneva, Grisons and Glarus, Valais, St. Gallen and 
Appenzell, Ticino, Zurich). Overall for the time period from 1990 to 2004, we found that 
22% of children registered in cantonal registries had not been registered in the SCCR.6 
Of these, 6% had been treated in a paediatric cancer centre belonging to SPOG, but 
had not been reported to the SCCR, and 16% had been treated in other hospitals, 
including paediatric hospitals and adult wards.  
  
                                               
2 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. 
Cancer 2005; 103:1457-67. 
3 World Health Organization. International Statistical Classification of Diseases for Oncology - Third Edition (ICD-O-3). 
Geneva: World Health Organization; 2000. 
4 World Health Organization. International Statistical Classification of Diseases and Related Health Problems - Tenth 
Revision. Geneva: World Health Organization; 1993. 
5 Michel G, von der Weid NX, Zwahlen M, Redmond S, Strippoli MPF, Kuehni CE. Incidence of childhood cancer in 
Switzerland: the Swiss Childhood Cancer Registry. Pediatric Blood & Cancer 2008; 50:46-51. 
6 Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, Probst-Hensch N, Niggli F, Kuehni CE. Access to 
specialized pediatric cancer care in Switzerland. Pediatric Blood & Cancer 2010; 54:721-7. 
9 
 
 
 
 
During the period covered in this study, the proportion of cases not treated in a 
paediatric cancer centre decreased, from 24% in 1990-1993 to 7% in 2002-2004. All 
additional cases identified by this study have since been included, so that completeness 
of the SCCR is now more than 95%.  
Based on these results, the SCCR changed its registration practice and now identifies 
cases from various sources, including regular data exchange with cantonal cancer 
registries, data collection from other hospitals or pathology laboratories and using 
information from mortality statistics (see chapter 5).  
Data protection 
In 2004, the SCCR received a special authorization (Sonderbewilligung) from the Swiss 
Federal Commission of Experts for Professional Secrecy in Medical Research. 
In June 2007, this was replaced by a general authorization (Generelle Bewilligung), 
which permits the collection of data on cancer in children and adolescents throughout 
Switzerland by obtaining written, oral or silent consent. A copy of the document provided 
by the expert commission can be downloaded from our homepage,7 together with 
explanations in French and German. At the time of diagnosis, all cases, treated in a 
Swiss paediatric oncology centre and their parents are informed by their treating 
physician about the childhood cancer registry. The patient has the right to stop transfer 
of non-anonymised data to the registry (veto power/possibility to opt out). Records of 
these cases are kept completely anonymised at all times. Information for cases is 
available from hospital brochures, hospital notice boards, parents and patients 
organisations. In the SCCR all case data are kept strictly confidential. Data with 
personal information (names, addresses) are stored separately from the clinical 
information.  
 
In 2010 data protection measures of the SCCR were examined by the Federal Data 
Protection and Information Commissioner and the cantonal data protection officer of 
Bern. In collaboration with these authorities the data collection and data storage was 
revised and refined. The new procedures were approved by the Federal Commission of 
Experts for Professional Secrecy in Medical Research. 
 
                                               
7 http://www.childhoodcancerregistry.ch/index.php?id=2451 
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Funding 
The SCCR thanks the following supporters for their financial contributions towards the 
daily running and continuous development of the registry. Supporters of scientific 
research projects are listed in Table 12 (page 34). 
 
Supporters 2009/10 
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3 Routine analyses covering cases diagnosed from 
1976-2009 
Overview 
The section on routine analyses includes three chapters. 
Chapter 3.1 describes the whole database, i.e. all children registered in the SCCR from 
1st January 1976 till 31st December 2009, with a diagnostic code contained in ICCC-3 
or a Langerhans cell histiocytosis (LCH), irrespective of the age at diagnosis. It includes 
adolescents aged 15 to 20 years. This age group is often treated in adult clinics and 
therefore its reporting and registration are incomplete in the SCCR. In addition, chapter 
3.1 includes some information on children resident in other countries but diagnosed and 
treated in Switzerland. 
Chapter 3.2 includes the core group of children aged 0-14 years and resident in 
Switzerland at the time of diagnosis. This is the age group usually covered in 
international publications therefore the tables and figures can be directly compared with 
data from other countries. Case registration in Switzerland is more than 95% complete 
for this age range, allowing the calculation of incidence and survival. 
Chapter 3.3 describes cases reported by different centres belonging to SPOG, 
irrespective of the age at diagnosis and the country of residence. 
 
3.1 Cases registered (N=6099) 
Up to 31st December 2009, a total of 6099 cases with a tumour coded according to 
ICCC-3, or a Langerhans cell histiocytosis (LCH), have been registered in the SCCR. Of 
these, 5429 (89%) were Swiss residents at the time of diagnosis and 563 (9%) were 
foreign residents (Table 1). Due to the Jules Gonin Eye Hospital in Lausanne, which 
treated 201 of 293 cases of retinoblastoma, among retinoblastoma cases 56% 
(163/293) were foreign residents. 
The SCCR started in 1976, initially with the registration of all cases participating in 
clinical trials. Since 1981, non-trial cases were also included, resulting in a significant 
increase in case numbers. There was a further increase in case registration in the early 
1990’s with the introduction of our electronic database (Figure 1). Since then, annual 
registration has remained stable. In the years 2005-2009, a total of 1117 new cases 
were registered, of whom 1011 were Swiss residents at the time of diagnosis (Table 2).  
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Table 1 – Total number of registered cases, by country of residence 
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years 
of diagnosis 1976-2009 (N=6099) 
 
 All ages 0-14 years >14 years 
Country of residence n % n % n % 
1 Switzerland 5429 89.0 5000 88.8 429 91.7 
2 Other countries 563 9.2 542 9.6 21 4.5 
a Europe 420 6.9 406 7.2 14 3.0 
 Neighbouring countries* 287 4.7 274 4.9 13 2.8 
 Other European countries 133 2.2 132 2.3 1 0.2 
b Middle East 8 0.1 8 0.1 0 0.0 
c North Africa 82 1.3 76 1.3 6 1.3 
d Other African countries 33 0.5 32 0.6 1 0.2 
e Other countries 20 0.3 20 0.4 0 0.0 
3 Country of residence missing 107 1.8 89 1.6 18 3.8 
TOTAL 6099 100.0 5631 100.0 468 100.0 
* Austria (N=10), France (N=71), Germany (N=58), Italy (N=111), Liechtenstein (N=37) 
 
Figure 1 – Annual number of registered cases over time 
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years 
of diagnosis 1976-2009 (N=6099) 
 
 
 
Annual number of cases 
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Table 2 – Number of cases registered, by period of diagnosis (5-year intervals) 
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years 
of diagnosis 1976-2009 (N=6099) 
 
Period of  Swiss residents 
diagnosis All cases n mean 
1976-1979* 377 325 81.3 
1980-1984 613 524 104.8 
1985-1989 766 639 127.8 
1990-1994 1072 945 189.0 
1995-1999 1050 950 190.0 
2000-2004 1104 1035 207.0 
2005-2009 1117 1011 202.2 
TOTAL 6099 5429 159.7 
* This period includes 4 years only 
 
 
 
3.2 Cases aged 0-14 years at diagnosis and resident in 
Switzerland (N=5000) 
This chapter includes cases aged 0-14 years and resident in Switzerland at the time of 
diagnosis, and with a diagnostic code according to ICCC-3 or a Langerhans cell 
histiocytosis. This is the age group usually covered in international publications; 
therefore the tables and figures can be compared directly to data from other countries. 
By 31st December 2009, the SCCR contained data from 5000 children who were both 
aged 0-14 years and resident in Switzerland at the time of diagnosis.  
 
Age at diagnosis 
Almost half of cases (46%) had been diagnosed between the ages of 0-4 years: 10% 
during infancy (0-1 year old) and 36% in the age group 1-4 years old (Figure 2). 
Incidence is lowest at age 9-10 years, and then increases again (Figure 3). As seen in 
other childhood cancer registries more boys than girls were diagnosed with cancer.  
 
  
14 
 
 
 
 
 
Figure 2 – Age at diagnosis  
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 1976-2009 (N=5000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Age at diagnosis, by sex 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 1976-2009 (N=5000)  
 
 
Number of cases 
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Diagnostic groups 
 
Table 3 – Diagnostic groups according to ICCC-3  
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1976-2009 (N=5000) 
 
  Total 
number 
Age at diagnosis (years) 
Diagnosis <1 1-4 5-9 10-14 
 n % n % n % n % n % 
I Leukaemias, myeoloproliferative diseases and myelodysplastic 
diseases 1711 34.2 64 12.7 824 45.8 477 35.7 346 25.5 
II Lymphomas and reticuloendothelial neoplasms 663 13.3 13 2.6 105 5.8 190 14.2 355 26.2 
III Central nervous system neoplasms 916 18.3 55 10.9 263 14.6 349 26.1 249 18.4 
IV Neuroblastoma and other peripheral nervous cell tumours 347 6.9 155 30.7 153 8.5 26 1.9 13 1.0 
V Retinoblastoma 130 2.6 62 12.3 60 3.3 7 0.5 1 0.1 
VI Renal tumours 276 5.5 42 8.3 159 8.8 66 4.9 9 0.7 
VII Hepatic tumours 49 1.0 16 3.2 18 1.0 6 0.4 9 0.7 
VIII Malignant bone tumours 215 4.3 0 0.0 17 0.9 66 4.9 132 9.7 
IX Soft tissue and other extraosseous sarcomas 310 6.2 32 6.3 94 5.2 77 5.8 107 7.9 
X Germ cell tumours, trophoblastic tumours and neoplasms of 
gonads 126 2.5 22 4.4 34 1.9 17 1.3 53 3.9 
XI Other malignant epithelial neoplasms and malignant melanomas 70 1.4 4 0.8 7 0.4 15 1.1 44 3.2 
XII Other specified and unspecified malignant neoplasms 13 0.3 2 0.4 4 0.2 0 0.0 7 0.5 
 Langerhans cell histiocytosis 174 3.5 38 7.5 63 3.5 42 3.1 31 2.3 
 TOTAL 5000 100.0 505 100.0 1801 100.0 1338 100.0 1356 100.0 
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Figure 4 – Diagnostic groups according to ICCC-3 and age at diagnosis (years) 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 1976-2009 (N=5000) 
 
The widths of the columns are proportional to the number of cases. 
 
 
 
 
 
 
 
 
Age at diagnosis (years) 
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Follow-up information 
The SCCR has several ways to collect follow-up information for registered cases:  
• Short-term clinical follow-up is done by paediatric haematology-oncology centres. 
Clinical follow-up usually ends 5-10 years after diagnosis when the patient is officially 
discharged or referred to an adult oncology centre, or if the patient dies. 
• Long-term epidemiological follow-up is done via three complementary 
approaches:  
o postal questionnaires to survivors in the Swiss Childhood Cancer Survivor Study 
(SCCSS, chapter 4, project 4) 
o systematic assessment of vital status by contacting community registries and 
linkage with the Swiss mortality statistics to retrieve causes of death (chapter 5) 
o detection of secondary cancers by regular comparison with cantonal (=regional) 
cancer registries in Switzerland  
Table 4 summarises the follow-up status of all cases aged 0-14 years at diagnosis. In 
total 1232 of the 5000 children (25%) died. Short-term clinical follow-up data is 
available for 1833 (37%) children for the period 2005-2009. For 428 (9%) and 600 (12%) 
children, the last clinical follow-up report is older, from 2000-2004 or before 2000 
respectively. These are mainly cases diagnosed before 1995. Long-term 
epidemiological follow-up data are available for the large majority of cases. Only 285 
(5.7%) of cases are lost to follow-up, mostly because they moved abroad. For the other 
3483 survivors, their vital status and current address have been updated during 2007-
10, and for 1457 of these we also have morbidity data from the SCCSS questionnaire 
survey from 2007-10. 
 
Table 4 – Follow-up information of cases in the SCCR databases 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 1976-2009 (N=5000) 
  Number of cases % 
Short-term clinical follow-up   
Died 1232 24.6 
Last clinical follow-up since Jan 2005 1833 36.7 
Last clinical follow-up 2000-2004 428 8.6 
Last clinical follow-up before 2000 600 12.0 
No clinical follow-up 907 18.1 
TOTAL  5000 100.0 
Long-term epidemiological follow-up   
Update of vital status, current address and current health 
via questionnaire survey (2007-2010)*  1457 29.1 
Update of vital status and current address via community 
registries only (2007-2010) 
2026 40.5 
Died, and causes of death retrieved from mortality statistics 1232 24.6 
Lost to follow-up (address and vital status unknown) 285 5.7 
TOTAL 5000 100.0 
* only cases diagnosed before 01.05.2003 were eligible for the SCCSS questionnaire survey  
18 
 
 
 
 
Survival 
Data on the survival of cases registered in the SCCR are presented for the first time in 
this report.  
 
Figure 5 shows an actuarial curve presenting overall survival up to 30 years after 
diagnosis for cases diagnosed between 1980-2009 (N=4694) grouped in three ten year 
periods. A total of 1076 children (23%) have died. Ten-year survival increased from 68% 
in children diagnosed between 1980-1989, to 75% in children diagnosed between 1990 
and 1999 and reached over 82% in children diagnosed in the last ten years.  
 
Figure 5 – Survival of cases in the SCCR, by period of diagnosis 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 1980-2009 (adjusted results for sex, age at 
diagnosis and ICCC-3 groups, N=4694) 
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Survival varies widely between diagnostic groups. Figure 6 presents survival for five 
diagnostic categories, in cases diagnosed from 2006-2009 (N=678). Five-year survival 
was above 80% in all diagnostic categories: it reached 93% for children diagnosed with 
leukaemias; 98% for those with lymphomas; 81% for children with central nervous 
system neoplasms; 88% for those with other tumours (including neuroblastoma, 
retinoblastoma, renal tumours, hepatic tumours, malignant bone tumours, soft tissue 
sarcomas, germ cell tumours, other specified and unspecified malignant neoplasms) 
and 100% in children diagnosed with Langerhans cell histiocytosis. 
 
Figure 6 – Survival of cases by diagnostic groups according to ICCC-3 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans 
cell histiocytosis), years of diagnosis 2006-2009 (adjusted results, N=678) 
 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
0 1 2 3 4 5 
Time since diagnosis (years) 
I Leukaemias (n=212) 
II Lymphomas (n=88) 
III Central nervous system neoplasms (n=145) 
IV-XII Other tumours (n=216) 
Langerhans cell histiocytosis (n=17) 
20 
% still alive 
 
 
 
 
Diagnosis (ICCC-3) for cases registered and resident in Switzerland  
Table 5 reports diagnosis according to ICCC-3 for all cases registered in the SCCR 
during the past 10 years (2000-2009). 
Overall more boys than girls were diagnosed with cancer. This was true for most types 
of tumours with the exception of neuroblastoma, germ cell tumours and other malignant 
epithelial neoplasms. 
The age-standardised incidence of any childhood cancer (not including Langerhans cell 
histiocytosis) was 14.8 cases per 100,000 person-years. Incidence was highest among 
children aged less than 1 year with 24.5 cases per 100,000 person-years and lowest in 
5-9 year olds with 11.7 cases per 100,000 person-years (Figure 7 showing crude 
incidence rates and Figure 8 showing age- and sex-specific incidence rates according 
to the European population for age-groups under 15 years8). 
The relative frequency of the different diagnoses, sex ratio, mean age at diagnosis and 
age-standardised incidence are similar to results from Germany.9  
 
 
                                               
8 J Waterhouse et al (eds). Cancer incidence in five continents. Lyon: International Agency for Research on Cancer, 
World Health Organization; 1976 (Vol. 3, p. 456). 
9 Kaatsch P, Spix C. Annual report 2008: German Childhood Cancer Registry (GCCR). Mainz; 2009. 
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Table 5 – Number of registered cases in the SCCR, sex ratio, mean age at diagnosis and age-standardised incidence* (per 100,000 person-
years), by diagnostic groups according to ICCC-3  
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 2000-2009 (N=1822) 
  n Relative Sex ratio Mean age Incidence* frequency (male: female) 
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases 565 31.8 1.3 4.9 4.7 
 a. Lymphoid leukaemias 460 81.4 1.3 4.8 3.8 
 b. Acute myeloid leukaemias 75 13.3 1.8 5.4 0.6 
 c. Chronic myeloproliferative diseases 3 0.5 2.0 11.0 0.0 
 d. Myelodysplastic syndrome and other myeloproliferative diseases 18 3.2 1.0 8.5 0.1 
 e. Unspecified and other specified leukaemias 9 1.6 1.3 3.3 0.1 
II Lymphomas and reticuloendothelial neoplasms 222 12.5 2.0 10.7 1.8 
 a. Hodgkin lymphomas 94 42.3 1.0 12.5 0.8 
 b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 79 35.6 3.2 9.1 0.7 
 c. Burkitt lymphoma 42 18.9 6.0 7.2 0.3 
 d. Miscellaneous lymphoreticular neoplasms 6 2.7 1.0 1.1 0.0 
 e. Unspecified lymphomas 1 0.5 0.0 13.6 0.0 
III CNS and miscellaneous intracranial and intraspinal neoplasms 419 23.6 1.2 6.9 3.5 
 a. Ependymomas and choroid plexus tumours 32 7.6 1.1 2.4 0.3 
 b. Astrocytomas 162 38.7 1.3 7.1 1.3 
 c. Intracranial and intraspinal embryonal tumours 97 23.2 1.6 5.4 0.8 
 d. Other gliomas 45 10.7 0.8 5.9 0.4 
 e. Other specified intracranial and intraspinal neoplasms 77 18.4 0.9 10.1 0.6 
 f. Unspecified intracranial and intraspinal neoplasms 6 1.4 1.0 9.1 0.0 
IV Neuroblastoma and other peripheral nervous cell tumours 119 6.7 0.9 1.0 1.0 
 a. Neuroblastoma and ganglioneuroblastoma 119 100.0 0.9 1.0 1.0 
V Retinoblastoma 38 2.1 0.7 1.0 0.3 
VI Renal tumours 94 5.3 1.1 3.0 0.8 
 a. Nephroblastoma and other nonepithelial renal tumours 91 96.8 1.2 2.9 0.8 
 b. Renal carcinomas 3 3.2 0.5 12.8 0.0 
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Table 5 – continued 
 
  n Relative Sex ratio Mean age  frequency (male: female) Incidence* 
VII Hepatic tumours 21 1.2 4.3 1.7 0.2 
 a. Hepatoblastoma 18 85.7 5.0 1.5 0.1 
 b. Hepatic carcinomas 3 14.3 2.0 13.9 0.0 
VIII Malignant bone tumours 91 5.1 1.0 10.6 0.8 
 a. Osteosarcomas 44 48.4 0.8 10.9 0.3 
 c. Ewing tumour and related sarcomas of bone 47 51.6 1.2 10.3 0.4 
IX Soft tissue and other extra osseous sarcomas 119 6.7 1.3 7.9 1.0 
 a. Rhabdomyosarcomas 74 62.2 1.6 5.3 0.6 
 b. Fibrosarcomas, peripheral nerve sheath tumours and other fibrous neoplasms 7 5.9 0.8 7.0 0.1 
 d. Other specified soft tissue sarcomas 28 23.5 1.0 11.9 0.2 
 e. Unspecified soft tissue sarcomas 10 8.4 1.0 7.3 0.1 
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 48 2.7 0.7 8.3 0.4 
 a. Intracranial and intraspinal germ cell tumours 8 16.7 3.0 9.5 0.1 
 b. Malignant extracranial and extragonadal germ cell tumours 16 33.3 0.3 1.8 0.1 
 c. Malignant gonadal germ cell tumours 23 47.9 0.6 12.0 0.2 
 d. Gonadal carcinomas 1 2.1 0.0 13.9 0.0 
XI Other malignant epithelial neoplasms and malignant melanomas 36 2.0 1.3 11.3 0.3 
 a. Adrenocortical carcinomas 1 2.8  2.0 0.0 
 b. Thyroid carcinomas 12 33.3 1.0 12.3 0.1 
 d. Malignant melanomas 15 41.7 0.9 8.6 0.1 
 e. Skin carcinomas 2 5.6  7.2 0.0 
 f. Other and unspecified carcinomas 6 16.7 2.0 12.0 0.0 
XII Other specified and unspecified malignant neoplasms 3 0.2 0.5 12.9 0.0 
 a. Other specified malignant tumours 1 33.3  12.9 0.0 
 b. Other unspecified malignant tumours 2 66.7 0.0 7.6 0.0 
 Total (not including Langerhans cell histiocytosis) 1'775 100.0 1.3 6.7 14.8 
 Langerhans cell histiocytosis 47 2.6 1.1 4.4 0.4 
 Total (including Langerhans cell histiocytosis) 1'822 100.0 1.3 6.7 15.1 
* Incidence: newly diagnosed cases in a one year time period per 100,000 persons  
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Figure 7 – Crude incidence rate (per 100,000 person-years) in Switzerland, by sex 
and year of diagnosis 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 but not including 
Langerhans cell histiocytosis), years of diagnosis 1990-2009 (N=3466) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Age- and sex-specific incidence rates (per 100,000 person-years) in 
Switzerland 
Swiss residents, aged 0-14 years at diagnosis, all diagnoses (ICCC-3 but not including  
Langerhans cell histiocytosis), years of diagnosis 2000-2009 (N=1775) 
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3.3 Cases reported by the 9 centres of the Swiss Paediatric 
Oncology Group 
Tables 6, 7 and 8 show the distribution of cases reported from the 9 SPOG centres for 
the periods 1976-1989, 1990-1999 and 2000-2009 respectively. Tables 9 and 10 show 
the numbers reported from the different SPOG centres in the years 2008 and 2009 
respectively. 
These tables include all cases irrespective of age and place of residence (Swiss and 
foreign cases). 
Cases reported for the years 1976-2009 
A total of 1756 cases were registered in the SCCR in the years 1976-1989. During the 
first period (1976-1989), most cases were reported from the paediatric haematology-
oncology centres of Bern (n=511, 29%), Zurich (n=293, 17%) and Lausanne (n=220, 
13%). For 6 cases the treating institution is unknown (Table 6). During the second 
period (1990-1999), 56% of cases were reported from the centres of Bern (n=416, 20%), 
Zurich (n=388, 18%) and Lausanne (n=386, 18%; Table 7). During the third period 
(2000-2009), a total of 2221 cases were reported (Bern, n=350, 16%; Zurich, n=574, 
26%; and Lausanne, n=410, 19%; Table 8). Most cases with retinoblastoma were 
reported by Lausanne (39%, 71% and 85% in the periods 1976-1989, 1990-1999 and 
2000-2009, respectively) because they are treated at the specialised Jules Gonin Eye 
Hospital at the University Hospital in Lausanne. 
Cases reported for the years 2008-2009 
The 9 SPOG centres reported 215 newly diagnosed cases to the SCCR in 2008 and 
186 in 2009 (Tables 9 and 10). The slight reduction in new cases in 2009 was mainly 
due to a lower number of leukaemias (63 in 2008 and 49 in 2009).  
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Table 6 – Number of children diagnosed* with cancer between 1976 and 1989, by participating paediatric oncology centre 
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1976 -1989 (N=1756) 
All cases irrespective of age and place of residency (Swiss and foreign cases) are included in this table. 
 
 Diagnosis Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne St Gallen Zurich Unknown‡ 
  n % n % n % n % n % n % n % n % n % n % n % 
I Leukaemias 664 100 50 7.5 75 11.3 194 29.2 59 8.9 56 8.4 2 0.3 49 7.4 70 10.5 106 16.0 3 0.5 
II Lymphomas 284 100 21 7.4 29 10.2 79 27.8 19 6.7 37 13.0 1 0.4 16 5.6 28 9.9 53 18.7 1 0.4 
III Central nervous system neoplasms 200 100 12 6.0 15 7.5 83 41.5 15 7.5 23 11.5 1 0.5 1 0.5 21 10.5 29 14.5 0 0.0 
IV Neuroblastoma 131 100 5 3.8 11 8.4 26 19.8 14 10.7 21 16.0 0 0.0 8 6.1 11 8.4 34 26.0 1 0.8 
V Retinoblastoma† 62 100 0 0.0 3 4.8 12 19.4 11 17.7 24 38.7 1 1.6 1 1.6 6 9.7 4 6.5 0 0.0 
VI Renal tumours 97 100 4 4.1 11 11.3 23 23.7 6 6.2 10 10.3 0 0.0 14 14.4 8 8.2 21 21.6 0 0.0 
VII Hepatic tumours 11 100 0 0.0 1 9.1 4 36.4 2 18.2 1 9.1 0 0.0 0 0.0 0 0.0 3 27.3 0 0.0 
VIII Malignant bone tumours 87 100 4 4.6 11 12.6 28 32.2 8 9.2 18 20.7 0 0.0 4 4.6 7 8.0 6 6.9 1 1.1 
IX Soft tissue sarcomas 109 100 3 2.8 13 11.9 35 32.1 8 7.3 14 12.8 0 0.0 10 9.2 10 9.2 16 14.7 0 0.0 
X Germ cell tumours 43 100 3 7.0 1 2.3 12 27.9 5 11.6 7 16.3 1 2.3 1 2.3 3 7.0 10 23.3 0 0.0 
XI Other malignant epithelial neoplasms 14 100 0 0.0 0 0.0 5 35.7 4 28.6 3 21.4 0 0.0 0 0.0 1 7.1 1 7.1 0 0.0 
XII Other specified and unspecified malignant 
neoplasms 
4 100 0 0.0 0 0.0 1 25.0 0 0.0 2 50.0 0 0.0 0 0.0 0 0.0 1 25.0 0 0.0 
 Langerhans cell histiocytosis 50 100 2 4.0 6 12.0 9 18.0 3 6.0 4 8.0 0 0.0 4 8.0 13 26.0 9 18.0 0 0.0 
 TOTAL 1'756 100 104 5.9 176 10.0 511 29.1 154 8.8 220 12.5 6 0.3 108 6.2 178 10.1 293 16.7 6 0.3 
 
* Diagnosis coded according to ICCC-3 and Langerhans cell histiocytosis 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown. This is usually the case for children indentified via pathology laboratories, cantonal cancer registries or mortality statistics 
 
  
26 
 
 
 
 
 
 
 
Table 7 – Number of children diagnosed* with cancer between 1990 and 1999, by participating paediatric oncology centre  
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 1990-1999 (N=2122)  
All cases irrespective of age and residency (Swiss and foreign cases) are included in this table. 
 
 Diagnosis Total Aarau Basel Bern Geneva Lausanne Locarno Lucerne St Gallen Zurich Unknown‡ 
  n % n % n % n % n % n % n % n % n % n % n % 
I Leukaemias 631 100 46 7.3 46 7.3 124 19.7 51 8.1 82 13.0 19 3.0 54 8.6 61 9.7 127 20.1 21 3.3 
II Lymphomas 256 100 17 6.6 24 9.4 42 16.4 25 9.8 41 16.0 12 4.7 18 7.0 15 5.9 48 18.8 14 5.5 
III Central nervous system neoplasms 398 100 22 5.5 28 7.0 105 26.4 33 8.3 49 12.3 12 3.0 9 2.3 26 6.5 78 19.6 36 9.0 
IV Neuroblastoma 135 100 3 2.2 17 12.6 20 14.8 13 9.6 27 20.0 1 0.7 10 7.4 10 7.4 27 20.0 7 5.2 
V Retinoblastoma† 140 100 0 0.0 6 4.3 5 3.6 7 5.0 100 71.4 1 0.7 7 5.0 4 2.9 6 4.3 4 2.9 
VI Renal tumours 109 100 2 1.8 11 10.1 23 21.1 11 10.1 13 11.9 0 0.0 5 4.6 11 10.1 30 27.5 3 2.8 
VII Hepatic tumours 24 100 0 0.0 3 12.5 7 29.2 0 0.0 4 16.7 1 4.2 0 0.0 1 4.2 8 33.3 0 0.0 
VIII Malignant bone tumours 116 100 2 1.7 20 17.2 28 24.1 19 16.4 17 14.7 3 2.6 4 3.4 6 5.2 11 9.5 6 5.2 
IX Soft tissue sarcomas 130 100 8 6.2 8 6.2 20 15.4 6 4.6 26 20.0 3 2.3 9 6.9 15 11.5 21 16.2 14 10.8 
X Germ cell tumours 62 100 4 6.5 8 12.9 11 17.7 5 8.1 9 14.5 1 1.6 1 1.6 3 4.8 16 25.8 4 6.5 
XI Other malignant epithelial neoplasms 28 100 2 7.1 3 10.7 6 21.4 1 3.6 3 10.7 2 7.1 1 3.6 0 0.0 2 7.1 8 28.6 
XII Other specified and unspecified malignant 
neoplasms 
9 100 0 0.0 3 33.3 0 0.0 0 0.0 1 11.1 0 0.0 0 0.0 0 0.0 0 0.0 5 55.6 
 Langerhans cell histiocytosis 84 100 3 3.6 9 10.7 25 29.8 2 2.4 14 16.7 3 3.6 5 6.0 9 10.7 14 16.7 0 0.0 
 TOTAL 2122 100 109 5.1 186 8.8 416 19.6 173 8.2 386 18.2 58 2.7 123 5.8 161 7.6 388 18.3 122 5.7 
 
* Diagnosis coded according to ICCC-3 and Langerhans cell histiocytosis 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown. This is usually the case for children indentified via pathology laboratories, cantonal cancer registries or mortality statistics 
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Table 8 – Number of children diagnosed* with cancer between 2000 and 2009, by participating paediatric oncology centre  
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), years of diagnosis 2000-2009 (N=2221)  
All cases irrespective of age and place of residency (Swiss and foreign cases) are included in this table. 
 
 Diagnosis Total Aarau Basel Bellinzona§ Bern Geneva Lausanne Locarno Lucerne St Gallen Zurich Unknown‡ 
  n % n % n % n % n % n % n % n % n % n % n % n % 
I Leukaemias 632 100 36 5.7 51 8.1 5 0.8 111 17.6 38 6.0 90 14.2 14 2.2 42 6.6 68 10.8 170 26.9 7 1.1 
II Lymphomas 291 100 22 7.6 17 5.8 3 1.0 50 17.2 17 5.8 45 15.5 5 1.7 34 11.7 30 10.3 60 20.6 8 2.7 
III Central nervous system neoplasms 524 100 21 4.0 28 5.3 4 0.8 91 17.4 33 6.3 89 17.0 10 1.9 19 3.6 34 6.5 172 32.8 23 4.4 
IV Neuroblastoma 127 100 7 5.5 9 7.1 0 0.0 19 15.0 8 6.3 25 19.7 0 0.0 9 7.1 10 7.9 40 31.5 0 0.0 
V Retinoblastoma† 91 100 1 1.1 3 3.3 0 0.0 3 3.3 0 0.0 77 84.6 0 0.0 2 2.2 1 1.1 3 3.3 1 1.1 
VI Renal tumours 99 100 9 9.1 6 6.1 1 1.0 17 17.2 9 9.1 11 11.1 4 4.0 6 6.1 7 7.1 29 29.3 0 0.0 
VII Hepatic tumours 24 100 4 16.7 0 0.0 0 0.0 4 16.7 3 12.5 2 8.3 1 4.2 0 0.0 4 16.7 5 20.8 1 4.2 
VIII Malignant bone tumours 125 100 5 4.0 22 17.6 0 0.0 16 12.8 12 9.6 27 21.6 2 1.6 1 0.8 12 9.6 26 20.8 2 1.6 
IX Soft tissue sarcomas 143 100 14 9.8 12 8.4 1 0.7 20 14.0 10 7.0 21 14.7 3 2.1 12 8.4 7 4.9 35 24.5 8 5.6 
X Germ cell tumours 61 100 9 14.8 2 3.3 0 0.0 4 6.6 6 9.8 11 18.0 1 1.6 5 8.2 7 11.5 12 19.7 4 6.6 
XI Other malignant epithelial neoplasms 50 100 2 4.0 4 8.0 0 0.0 6 12.0 1 2.0 3 6.0 0 0.0 6 12.0 7 14.0 10 20.0 11 22.0 
XII Other specified and unspecified malignant 
neoplasms 
7 100 0 0.0 3 42.9 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 0 0.0 0 0.0 1 14.3 2 28.6 
 Langerhans cell histiocytosis 47 100 5 10.6 4 8.5 0 0.0 9 19.1 1 2.1 9 19.1 1 2.1 1 2.1 6 12.8 11 23.4 0 0.0 
 TOTAL 2221 100 135 6.1 161 7.2 14 0.6 350 15.8 139 6.3 410 18.5 41 1.8 137 6.2 193 8.7 574 25.8 67 3.0 
 
* Diagnosis coded according to ICCC-3 and Langerhans cell histiocytosis 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown. This is usually the case for children indentified via pathology laboratories, cantonal cancer registries or mortality statistics 
§ Since 2008 cases of Ticino are treated in Bellinzona 
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Table 9 – Number of children diagnosed* with cancer in 2008, by participating paediatric oncology centre  
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), new cases diagnosed in 2008 (N=215) 
All cases irrespective of age and place of residence (Swiss and foreign cases) are included in this table. 
 
 Diagnosis Total Aarau Basel Bellinzona Bern Geneva Lausanne Lucerne St Gallen Zurich Unknown‡ 
I Leukaemias 63 2 6 1 11 2 13 5 7 16 0 
II Lymphomas 29 4 1 2 3 2 3 3 5 5 1 
III Central nervous system neoplasms 43 1 3 2 7 2 8 1 4 14 1 
IV Neuroblastoma 20 0 0 0 4 2 8 0 1 5 0 
V Retinoblastoma† 7 0 0 0 0 0 7 0 0 0 0 
VI Renal tumours 8 1 0 1 2 0 0 1 0 3 0 
VII Hepatic tumours 1 0 0 0 0 0 0 0 1 0 0 
VIII Malignant bone tumours 15 0 2 0 3 1 2 0 4 3 0 
IX Soft tissue sarcomas 13 3 0 0 1 0 3 1 1 4 0 
X Germ cell tumours 7 2 0 0 0 1 1 0 1 2 0 
XI Other malignant epithelial neoplasms 5 0 1 0 1 0 0 0 0 1 2 
XII Other specified and unspecified malignant 
neoplasms 
0 0 0 0 0 0 0 0 0 0 0 
 Langerhans cell histiocytosis 4 0 0 0 1 0 1 0 0 2 0 
 TOTAL 215 13 13 6 33 10 46 11 24 55 4 
 
* Diagnosis coded according to ICCC-3 and Langerhans cell histiocytosis 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
‡ Treating institution unknown. This is usually the case for children indentified via pathology laboratories, cantonal cancer registries or mortality statistics 
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Table 10 – Number of children diagnosed* with cancer in 2009, by participating paediatric oncology centre 
Including all age groups, all diagnoses (ICCC-3 or Langerhans cell histiocytosis), new cases diagnosed in 2009 (N=186) 
All cases irrespective of age and place of residence (Swiss and foreign cases) are included in this table. 
 
 Diagnosis Total Aarau Basel Bellinzona Bern Geneva Lausanne Lucerne St. Gallen Zurich 
I Leukaemias 49 4 3 4 5 2 7 5 3 16 
II Lymphomas 25 1 1 0 2 0 4 3 3 11 
III Central nervous system neoplasms 42 1 2 2 5 3 7 7 1 14 
IV Neuroblastoma 16 3 1 0 1 1 2 1 1 6 
V Retinoblastoma† 7 1 1 0 0 0 5 0 0 0 
VI Renal tumours 10 0 1 0 2 0 1 1 0 5 
VII Hepatic tumours 4 0 0 0 2 1 0 0 0 1 
VIII Malignant bone tumours 8 0 1 0 0 0 3 0 0 4 
IX Soft tissue sarcomas 15 2 1 1 2 0 3 1 0 5 
X Germ cell tumours 4 0 0 0 0 0 1 0 0 3 
XI Other malignant epithelial neoplasms 4 0 0 0 0 0 0 2 1 1 
XII Other specified and unspecified malignant 
neoplasms 
0 0 0 0 0 0 0 0 0 0 
 Langerhans cell histiocytosis 2 0 1 0 0 0 0 0 0 1 
 TOTAL 186 12 12 7 19 7 33 20 9 67 
 
* Diagnosis coded according to ICCC-3 and Langerhans cell histiocytosis 
† Most cases with retinoblastoma are treated at the specialised Jules Gonin Eye Hospital at the University Hospital in Lausanne 
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4 Current research projects with data from the SCCR 
The section on current research projects at the SCCR includes two chapters. 
Chapter 4.1 lists studies conducted in one or several centres of the Swiss Paediatric 
Oncology Group (SPOG), where the SCCR provided data or performed the statistical 
analyses. 
Chapter 4.2 describes recent or current research projects, which are conducted within 
the Child and Adolescent Health group at the Institute of Social and Preventive Medicine 
(ISPM), University of Bern.  
We thank the supporters, listed in Table 12 for their generous contributions towards the 
research projects. 
 
 
4.1 Collaboration in research projects of the Swiss Paediatric 
Oncology Group 
The overview describes projects initiated and led by SPOG members or where SPOG 
members are participating (single centre and multi centre projects, MD theses and PhD 
theses). The SCCR contributed by providing data from the SCCR database or by 
participating in the data analysis and interpretation. 
Table 11 includes a list of these projects since 2007, with related publications. 
 
 
4.2 Research projects conducted at the SCCR  
This section relates to research projects initiated and conducted at the SCCR (located at 
the ISPM Bern), mainly using data from the SCCR, often in combination with additionally 
collected data (questionnaires) and sometimes using comparison data from other 
national datasets (such as the Swiss National Cohort or the Swiss Health Surveys).  
 
Table 12 gives an overview of all recent and ongoing research projects conducted at the 
SCCR between 2005 and 2010. They are described in more detail in the remainder of 
chapter 4. Additional information is available from the references and from the 
investigators.  
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Table 11 – Collaboration in projects / studies conducted by the Swiss Paediatric Oncology Group since 2007 
 
Title Investigator Population Data extracted Date of data 
extraction 
Publications 
Primitive neuroectodermal 
tumour (PNET), 
Medulloblastoma and 
Trisomy 21, update 2010 
N. von der Weid, 
Lausanne 
All cases with PNET, 
Medulloblastoma and prior 
relevant diseases (Trisomy 
21) 
Diagnosis and prior relevant 
diseases 
Dec 10 Publication in preparation 
(international collaboration) 
Malnutrition in childhood 
cancer cases, MSc thesis 
K. Zimmermann, 
Bern 
All cases from Bern, Basel, 
and Zurich, diagnosed 
between 2004-2006 treated 
with chemo- or 
radiotherapy 
Institution, date of birth, sex, 
diagnosis, date of diagnosis, 
state of tumour, protocol, 
nationality 
Feb 10 Master thesis of Karin 
Zimmermann, MSc Health care 
science, March 2010 
Publication in preparation 
Epidemiological study 
about neurocognitive late 
effects in children with 
tumour or leukaemia 
K. Leibundgut, 
Bern 
All cases diagnosed 
between 2004-2008, with 
ICCC-3 code or 
Histiocytosis 
ICCC-3, age at diagnosis, 
year of diagnosis. 
Calculation of prevalence 
Dec 09 Feasibility study finished, grant 
application in preparation  
Current address research 
for cases from cerebral 
tumour database Zurich 
M. Grotzer,   
Zurich 
Cases with cerebral tumour Current addresses Mar 09 Ongoing project 
Annual Report  N. von der Weid, 
Lausanne 
Cases with diagnosis date 
between 01.11.07–
31.10.08 
Diagnosis, year of 
diagnosis, year of relapse 
Feb 09 Annual report 2009 SPOG 
Primitive neuroectodermal 
tumour (PNET), 
Medulloblastoma and 
Trisomy 21 
N. von der Weid, 
Lausanne 
All cases with PNET, 
Medulloblastoma and prior 
relevant diseases (Trisomy 
21)  
Diagnosis and prior relevant 
diseases 
Nov 08 Publication in preparation 
(international collaboration) 
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Table 11 - continued 
 
Title Investigator Population Data extracted Date of 
data 
extraction 
Publications 
Annual Report N. von der Weid, 
Lausanne 
Cases with diagnosis date 
between 01.11.06–31.10.07 
Diagnosis, year of 
diagnosis, year of relapse 
Feb 08 Annual report 2008 SPOG 
Wilms tumour, Soft tissue 
sarcoma (STS) and 
autologous bone marrow 
transplantation (BMT) 
N. von der Weid, 
Lausanne 
All cases with Wilms tumour 
or STS who had autologous 
bone marrow 
transplantation  
Diagnosis, year of 
diagnosis, autologous BMT 
May 07 Retrospective request of the 
European Group for Blood and 
Marrow Transplantation (EBMT) 
Childhood acute myeloid 
leukaemias (AML): clinical 
significance of cytogenetic 
events at presentation and 
relapse 
D. Betts, Zurich All cases with AML 
registered in the SCCR  
All information on case, 
tumour and therapy levels. 
Calculation of survival.  
Feb 07 Betts DR et al. European Journal 
of Haematology 2007 10 
Craniopharyngeoma 
cases in Bern 
M. Janner, Bern All cases with a 
Craniopharyngeoma from 
Bern  
Names, dates of birth and 
diagnosis, sex 
Jan 07 Presentation at an internal 
meeting, University Children’s 
Hospital, Bern 
 
For earlier collaborations (before 2007) please refer to the previous Annual Report 2007/2008 
                                               
10 Betts DR. et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG). European Journal of 
Haematology 2007; 78:468-76. 
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Table 12 – Research projects conducted at the SCCR since 2005 
 
No Project name Funding Primary 
investigator 
Study Type Study period 
1 Childhood Cancer and Nuclear Power Plants in 
Switzerland - CANUPIS 
Federal Office of Public Health 
(FOPH) 
Swiss Cancer League 
Kuehni CE Cohort study 09.2008-12.2010 
2 Childhood cancer and vicinity of residence to petrol 
stations and major roads: a census-based nationwide 
cohort study 
Federal Office of Public Health 
(FOPH)  
Feller M  
Kuehni CE 
Cohort study 06.2010-11.2012 
3 Developing a radon exposure model to predict domestic 
radon exposure for Swiss children 
Swiss National Science 
Foundation 
Röösli M Cohort study 01.2011-12.2013 
4 Swiss Childhood Cancer Survivor Study (SCCSS) Oncosuisse von der Weid NX 
Kuehni CE 
Cohort study  01.2006-08.2010 
5 Follow-up care after childhood and young adult cancer 
(CCFU) 
Swiss National Science 
Foundation 
Michel G Cohort study 08.2009-07.2012 
6 Risk of cancer and long-term mortality in children treated 
with Growth Hormone: Swiss participation in the EU FP7 
project “SAGhE” 
EU FP7 
Oncosuisse 
Mullis P 
Kuehni CE 
Cohort study 01.2010-08.2012 
7 Childhood leukaemia and lymphoma: are incidence and 
survival in Switzerland associated with socio-economic 
status?  
Oncosuisse Zwahlen M Case-control 
study / Cohort 
study 
08.2007-07.2009  
8 An international case-control study on brain tumours in 
children and adolescents - CEFALO 
Swiss Research Foundation 
on Mobile Communication  
Federal Office of Public Health 
(FOPH) 
Swiss National Science 
Foundation (Pro Doc Grant) 
Röösli M Case-control 
study 
10.2005-12.2008 
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Project 1 – Childhood Cancer and Nuclear Power Plants in Switzerland - 
CANUPIS 
 
 
This study addresses the question if residence in the proximity of a nuclear power plant 
(NPP) is associated with an increased risk of childhood cancer, and whether this can be 
explained by confounding, particularly by other area-based risk factors for childhood 
cancer which might cluster around nuclear power plants. Details are available from the 
CANUPIS-Homepage: www.canupis.ch. 
 
Background: Since the reporting of a cluster of leukaemia cases around Sellafield in 
1984, numerous studies have assessed the risk of childhood cancer and residence in 
the proximity of nuclear power plants (NPPs). These studies showed heterogeneous 
results, many with weak positive associations. An explanation for this excess is lacking. 
Emissions from NPPs during normal operation are low in comparison to the annual 
background exposure and dose-response studies do not support a causal association. A 
recent case-control study from Germany, showing a small but statistically significant 
increase in the risk of cancer, particularly leukaemia, in children aged less than five 
years and living near NPPs refuelled the public discussion about this potential hazard. 
The study, as many others, had methodological problems limiting the interpretability of 
the results, including i) a potential selection bias because of differential response rates 
of municipalities; ii) possible bias due to the selection of controls by local clerks; iii) lack 
of adjustment for potential confounding factors such as electric power lines, major 
roads, socio-economic status, and other factors; and iv) analysis of residency only at the 
time of cancer diagnosis (because of the known latency in the development of malignant 
diseases, the place of residence prior to the diagnosis is of great interest). 
 
Objectives: To investigate whether living near a NPP increases the risk of childhood 
cancer in general, and childhood leukaemia in particular. 
 
Methods: This is a census-based cohort study with national coverage. Selection bias is 
minimized by using geo-coded addresses for each child, adjusting for important 
potential confounders, and inclusion of residential history back to the date of birth. The 
study uses the Swiss National Cohort (SNC), a long-term, census-based, multipurpose 
cohort and research platform including all Swiss inhabitants (6.8 million people) to 
estimate person-years at risk. Cases are identified via the Swiss Childhood Cancer 
Registry (SCCR). Included are all cases born between January 1985 and December 
2007, aged less than16 years at diagnosis and resident in Switzerland. Our main 
exposure is proximity to nuclear sites modelled as four categories (the inner 5 km zone, 
5-10 km, 10-15 km and more than 15 km). The following confounders are included: 
distance to major roads, electric power lines and broadcast transmitters, natural ionising 
radiation, area statistics (e.g. pesticides from agriculture or golf courses), pollutants from 
industry, degree of urbanisation, socio-economic status (using the Sotomo-Index11) and 
average number of children per family at communal level. 
 
Rational and significance: This study will add importantly to the current evidence base 
on the risk of childhood cancer and residence in the proximity of nuclear sites. It will 
overcome important methodological problems of previous studies. Given the fact that 
additional nuclear sites are currently planned in Switzerland, the topic is of high public 
health and policy relevance. 
 
  
                                               
11 Hermann M, Heye C, Leuthold H. Soziokulturelle Unterschiede in der Schweiz - Vier Indizes zu räumlichen 
Disparitäten, 1990–2000 In: Bundesamt für Statistik (BFS)s pp. 70. Neuchâtel: Bundesamt für Statistik, 2005, 
http://sotomo.geo.unizh.ch/papers/soziokult.pdf. 
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Study Team 
 
Applicants: Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; 
Röösli M. Swiss Tropical and Public Health Institute, University of Basel; Von der Weid 
NX. Paediatric Oncology, CHUV Lausanne; Hengartner H. Ostschweizer Kinderspital,  
St. Gallen; Niggli F. University Children’s Hospital, Zurich; Egger M. Institute of Social 
and Preventive Medicine, University of Bern. 
Project team: Feller M, Kuehni CE, Spycher B, Zwahlen M, Gueler A, Institute of Social 
and Preventive Medicine, University of Bern.  
 
Funding: Federal Office of Public Health (FOPH); Swiss Cancer League  
 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch) 
 
Publications: Expected for 2011 
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Project 2 – Childhood cancer and vicinity of residence to petrol stations 
and major roads: a census-based nationwide cohort study 
 
 
Background: The aetiology of childhood cancer is not well understood and research on 
possible causal agents is required. Benzene is a traffic-related air pollutant, which is 
known to be haematotoxic and an established carcinogen in humans. The association 
with acute myeloid leukaemia is well documented in adults, but data on children are 
scarce. 
 
Objective: To examine whether residence in the proximity of petrol stations, motor 
vehicle service stations or major roads as well as parental profession-related exposure 
to benzene is associated with an increased risk of any type of cancer and of leukaemia 
in Swiss children and adolescents aged 0-19 years. 
 
Methods: The study will include all children born between January 1985 and December 
2008, aged <20 years and resident in Switzerland. Analyses will be based on 
information obtained from the SCCR, the Swiss National Birth Registry (NBR) and the 
Swiss National Cohort (SNC), a long-term, census-based cohort that includes all Swiss 
inhabitants (6.8 million people). All addresses will be geo-coded to assess proximity to 
petrol stations, motor vehicle stations and major roads. Data sources are the census of 
business and the Teleatlas database.  
From January 1985 to December 2008 about 4500 children and adolescents aged <20 
years were diagnosed with cancer in Switzerland, including 1300 with acute leukaemia. 
As the main exposure we will calculate proximity to petrol stations, motor vehicle service 
stations or major roads. Additionally we will analyse if children with one or both parents 
working in benzene-exposed occupations are at higher risk for childhood cancer than 
children whose parents do not work in benzene-exposed occupations. Information on 
occupation will be extracted from the 1990 and 2000 censuses. The data will be 
analysed using Poisson regression models, adjusting for a range of potential 
confounders, including the socio-economic status of parents, maternal and paternal age 
at birth, birth weight and length, birth order, and the number of siblings. 
 
Rational and Significance: Traffic-related pollution and its effects on health are a major 
public health issue because a substantial proportion of the population is exposed. This 
unique, large-scale study will make an important contribution to the evidence on a 
possible association between traffic-related air pollution and childhood cancer. 
 
 
 
Study Team 
 
Applicants: Feller M, Spoerri A. Institute of Social and Preventive Medicine, University 
of Bern; Von der Weid NX. Paediatric Oncology, CHUV Lausanne; Zwahlen M, Egger 
M, Kuehni CE. Institute of Social and Preventive Medicine, University of Bern;  
Project team: Mueller M, Spoerri A, Zwahlen M, Gueler A, Kuehni CE. Institute of 
Social and Preventive Medicine, University of Bern. 
 
Funding: Federal Office of Public Health (FOPH) 
 
Contact: Claudia Kuehni (kuehni@ispm.unibe.ch) 
 
Publications: Expected for 2012 
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Project 3 – Developing a radon exposure model to predict domestic radon 
exposure for Swiss children 
 
 
Background: Although cancer in children under 15 years of age is rare, it was the 
second most common cause of death in children in the United States in 2005 and the 
third most common cause of death in children in the European Union in 2000 and also 
accounts for a high burden of disability because of late effects in survivors. There is 
evidence that radon exposure is associated with lung cancers in adults, but less is 
known with respect to the association with childhood cancers. Studies published on this 
issue so far are ecological studies that do not control for possible confounders or case-
control studies with inconsistent results and possible recall and selection bias.  
 
Objectives: To develop a radon exposure model and to predict domestic radon 
exposure for children in Switzerland. To investigate if an elevated indoor radon 
concentration increases the risk of childhood cancer in general, and of acute 
lymphoblastic leukaemia (ALL) in particular. 
 
Methods: A prospective census-based cohort design will be used to investigate the 
potential association between radon exposure and childhood cancer. All children aged 
between 0 and 15 years, born before 4th December 2000 (date of census) and resident 
in Switzerland will be included in the cohort. Follow-up period will last until death, 
emigration or 31st December 2007. The SCCR will be used to identify eligible cases. In 
total, roughly 1000 childhood cancer cases, with approximately 250 ALL cases will be 
included. The Swiss National Cohort (SNC) will provide the place of residency on the 
date of census for all children of the cohort, mortality and emigration data for the 
calculation of follow-up time, and information about potential confounding factors such 
as socio-economic status or number of children in the household. The CANUPIS study 
(Childhood cancer and nuclear power plants in Switzerland) will provide residential 
history for all cancer cases. In order to assess individual exposure to radon at the place 
of residency, a model for domestic radon exposure will be developed using the radon 
data base of the Swiss Federal Office of Public Health and geographically referenced 
information (e.g. building register, geology). The radon database consists of indoor 
measurements for about 100,000 buildings in Switzerland. The prediction model will be 
validated with independent indoor radon measurements. Thereby, the aim is to use 20% 
of data from each canton for the model validation. Exposure to spatially variable 
potential confounders such as power lines or distance to streets will be calculated using 
geographic information systems (GIS). The data will be analyzed using established 
statistical methods for cohort studies, primarily Cox regression models adjusted for 
potential confounders. 
 
Rationale and significance: This is a census-based cohort study with national 
coverage. Important potential confounders will be adjusted for and selection bias will be 
minimized because no direct contact with study participants is necessary. Thus, this 
study will be able to overcome major methodological problems of most previous studies 
on that topic and add significant insight to the open issue whether low dose ionizing 
radiation is associated with childhood cancer. The study will also provide novel 
information relating to the exposure of the Swiss population to radon by combining 
available measurements with modelling. Radon represents a preventable exposure. It is 
estimated to contribute to roughly half of the average annual ionizing radiation dose in 
Switzerland. Thus, the topic is of high public health relevance if radon is associated with 
childhood cancer. 
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Study Team 
 
Applicants: Röösli M. Swiss Tropical and Public Health Institute Basel; Kuehni CE. 
Institute of Social and Preventive Medicine, University of Bern; Huss A. Institute for Risk 
Assessment Sciences, Utrecht University, The Netherlands  
Project team: Hauri D, Röösli M. Swiss Tropical and Public Health Institute Basel; 
Kuehni CE. Institute of Social and Preventive Medicine, University of Bern; Zimmermann 
F. University Hospital Basel 
 
Funding: Swiss National Foundation (SNF) 
 
Contact: Martin Röösli (martin.roosli@unibas.ch) 
 
Publications: Expected for 2011-2013 
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Project 4 – Swiss Childhood Cancer Survivor Study (SCCSS) 
 
 
This is a survey of all long-term survivors (≥5 years after diagnosis) of childhood cancer 
in Switzerland, to assess the somatic and psychosocial late effects, health behaviours 
and health-related quality of life. 
 
Background: Thanks to therapeutic improvements in the past decades, survival rates in 
childhood cancer now exceed 80%, leading to a growing population of long-term 
survivors. However, cancer and cancer treatments have been associated with adverse 
late effects. Therefore, the health and quality of life of survivors are a matter of 
increasing concern. In Switzerland and elsewhere, comprehensive data on the burden 
of late effects of childhood cancer and its risk factors, and data on use of follow-up care 
in long-term survivors are scarce. 
 
Objectives: This project investigates the long-term outcome of former childhood cancer 
cases who were diagnosed with cancer before the age of 16 and who survived for more 
than 5 years. It studies the incidence and spectrum of various somatic and psycho-
social outcomes (late mortality, secondary malignancies, endocrine disorders, infertility, 
cardiovascular events, psychological distress, educational achievement etc.) and health 
related quality of life (HRQoL), and their association with a number of risk factors 
assessed prospectively at the time of diagnosis (tumour, treatment modalities, 
demographic characteristics). In addition, the current practice of health-care provision 
and health behaviour in long-term survivors are investigated. 
 
Methods: This is a prospective cohort study based on the population of children 
registered in the SCCR. Eligible for the study are 2738 individuals, who have been 
diagnosed before 1st May 2003 (i.e. at least 5 years prior to the beginning of the study), 
who are still alive, and who were Swiss residents at the time of diagnosis. The study 
population includes 1647 adults (≥ 20 years), 470 adolescents (15 – 20 years), and 621 
children (5 – 15 years). 
A detailed questionnaire is being sent to all participants, assessing demographic and 
socio-economic information, educational and professional achievements, current 
medical conditions and treatments, health-related quality of life (HRQoL), psychological 
well-being, health behaviour and healthcare provision. If consent is given, questionnaire 
data will be complemented with, and validated against general practitioner and hospital 
records. For comparing the results, the same questionnaire is being sent to all siblings 
of childhood cancer survivors who answered a questionnaire. 
 
Rationale and significance: The existing database of the SCCR gives the rare 
opportunity for a nationwide study on long-term outcomes in survivors of childhood 
cancer. The project will increase the knowledge on the incidence of, and risk factors for 
late effects, and provide a summary of the current status of care in Switzerland. As 
many late effects can be prevented or cured if diagnosed early, this study will also 
contribute to improving the health of current and future survivors of childhood cancer. 
 
Current status of the project: Up to August 2010, 1193 adult survivors had answered 
a questionnaire (78% of those contacted) as well as 312 adolescent survivors (69% of 
those contacted). The questionnaire for children was sent out in November 2010 and 
January 2011. Of the 749 siblings that could be traced and contacted, 451 (60%) 
answered the questionnaire. In 2011 the study population will be expanded and 
survivors diagnosed until 31.12.2005 will be included in the study. Some results from 
adult survivors have already been analysed and published (see below). 
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Study Team 
 
Applicants: Von der Weid NX. Paediatric Oncology, CHUV Lausanne; Kuehni CE, 
Egger M, Zwahlen M. Institute of Social and Preventive Medicine, University of Bern; 
Probst-Hensch N. Department of Pathology / Department of Social and Preventive 
Medicine, University Hospital, Zurich; Niggli F. University Children’s Hospital, Zurich. 
Project team: Rüegg CS, Rebholz CE, Wengenroth L, Kuehni CE, Michel G, Koch J, 
Gianinazzi M. Institute of Social and Preventive Medicine, University of Bern; Von der 
Weid NX. Paediatric Oncology, CHUV Lausanne; Niggli F. University Children’s 
Hospital, Zurich. 
 
Funding: Swiss Cancer League (Grant No KLS-01605-10-2004 and KLS-2215-02-
2008), Bernese Cancer League and Cancer League Zurich. 
 
Contact:  Corina Rüegg (crueegg@ispm.unibe.ch), 
Claudia Kuehni (kuehni@ispm.unibe.ch) 
 
Publications 
Rebholz CE, von der Weid NX, Michel G, Niggli F, Kuehni CE. Follow-up care amongst 
long-term childhood cancer survivors: a report from the Swiss Childhood Cancer 
Survivor Study. European Journal of Cancer 2011; 41:221-9. 
Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C, Rueegg CS, von der Weid 
NX. Can health beliefs help explaining attendance to follow-up care? The Swiss 
Childhood Cancer Survivor Study. Psycho-Oncology 2010; doi:10.1002/pon.1823 
Marquis A, Kuehni CE, Strippoli MPF, Kuehne T, Brazzola P. Sperm analysis of patients 
after successful treatment of childhood acute lymphoblastic leukemia with 
chemotherapy. Pediatric Blood & Cancer 2010; 55:208–10. 
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological 
distress in adult childhood cancer survivors: the Swiss Childhood Cancer Survivor 
Study. Journal of Clinical Oncology 2010; 28:1740-7. 
Rueegg CS, Rebholz CE, Michel G, von der Weid NX, Zwahlen M, Grotzer M, Kuehni 
CE. Daily physical activity and sports in adult survivors of childhood cancer and healthy 
controls. Submitted. 
Rebholz CE, Spycher BD, Rueegg CS, Michel G, Ammann RA, von der Weid NX, 
Kuehni CE. Clustering of health behaviours in adult survivors of childhood cancer and 
the general population. Submitted. 
Kuehni CE, Strippoli MPF, Rueegg CS, Rebholz CE, Bergstraesser E, Grotzer M, von 
der Weid NX, Michel G. Educational achievement in Swiss childhood cancer survivors 
compared to the general population. Submitted. 
Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MPF, Niggli F, Egger M, von 
der Weid NX. Cohort profile: the Swiss Childhood Cancer Survivor Study. Submitted. 
Rebholz CE, Kuehni CE, Strippoli MPF, Rueegg CS, Michel G, Hengartner H, 
Bergstraesser E, von der Weid NX. Alcohol consumption and binge drinking in young 
adult childhood cancer survivors: a report from the Swiss Childhood Cancer Survivor 
Study. Submitted. 
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Project 5 – Follow-up care after childhood and young adult cancer (CCFU) 
 
 
This is a survey of long-term survivors (≥5 years) of childhood cancer, oncologists, 
haematologists and family practitioners in Switzerland, to assess the current use of 
follow-up care and preferences / opinions for a future Swiss model of follow-up care. 
 
Background: Treatment for cancer in children and young adults has greatly improved 
and most cases are being cured. However, more than 50% of survivors of childhood 
cancer suffer from late effects. To detect and treat late effects as early as possible it is 
important that survivors continue to visit follow-up care long after they have been cured 
from cancer. Various models of follow-up care have been described but so far none has 
been implemented in Switzerland. While follow-up care needs to be constantly updated 
according to the current status of research, it is also important that it is convenient for 
survivors to participate. 
 
Objectives: 1) To compare the advantages and disadvantages of follow-up care models 
currently used in Europe. 2) To determine the current availability and use of follow-up 
care in survivors of childhood and young adult cancers in Switzerland. 3) To determine 
the advantages and disadvantages of follow-up care models as perceived by survivors, 
oncologists and family practitioners, and to compare their views and opinions. 
 
Methods: For part 1, we invited 198 clinics and follow-up programmes in Europe to 
complete a questionnaire survey describing the follow-up care available at their 
institution. For part 2, we analysed the current use of follow-up care (Michel et al. 
Psycho-Oncology 2010) together with the psychological well-being in childhood cancer 
survivors (Michel et al. Journal of Clinical Oncology 2010) using data from the Swiss 
Childhood Cancer Survivor Study (SCCSS). In part 3, a questionnaire survey will assess 
opinions and perspectives on both currently used and desired optimal follow-up care. 
The sample includes childhood, adolescent and young adult cancer survivors who were 
diagnosed with cancer between 1990 and 2005 and aged under 25 years, who have 
survived for more than 5 years and who are currently aged 11 years and older. In 
addition, paediatric and adult oncologists and haematologists, and family practitioners 
will fill in a questionnaire. 
 
Rationale and significance: This project provides an overview of the follow-up care 
used in Europe and will describe the preferences for follow-up care models in survivors, 
oncologists and family practitioners in Switzerland. Differences between the three 
groups will be determined in order to improve follow-up care in the future, adapting it to 
differing preferences. The project will provide the basis for the development of a 
standardised model of follow-up care for childhood cancer survivors in Switzerland. 
 
 
 
Study Team 
 
Applicant: Michel G. Institute of Social and Preventive Medicine, University of Bern. 
Project team: Michel G, Kuehni CE, Egger M, Hohn A. Institute of Social and 
Preventive Medicine, University of Bern; Von der Weid NX. Paediatric Oncology, CHUV 
Lausanne; Niggli F. University Children’s Hospital, Zurich. 
 
Funding: Swiss National Science Foundation (Division Individual Funding “Ambizione” 
Grant No. PZ00P3_121682/1) 
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Collaborations  
Eiser C, Greenfield D. Child and Family Research Group, University of Sheffield. Hjorth 
L, Skinner R, Haupt R, Hawkins M, Kremer L. PanCare (European network of 
professionals, survivors and their families established to ensure that every European 
survivor of childhood and adolescent cancer receives optimal long-term care) 
 
Contact: Gisela Michel (michel@ispm.unibe.ch) 
 
Publications 
Michel G, Kuehni CE, Rebholz CE, Zimmermann K, Eiser C, Rueegg CS, von der Weid 
NX. Can health beliefs help explaining attendance to follow-up care? The Swiss 
Childhood Cancer Survivor Study. Psycho-Oncology 2010; DOI: 10.1002/pon.1823 
Michel G, Greenfield D, Absolom K, Eiser C. Follow-up care after childhood and young 
adult cancer: Satisfaction and associations with coping style. Psycho-Oncology 2010; 
DOI:10.1002/pon.1783 
Rebholz CE, von der Weid NX, Michel G. Niggli F, Kuehni CE. Follow-up care amongst 
long-term childhood cancer survivors: a report from the Swiss Childhood Cancer 
Survivor Study. European Journal of Cancer 2011; 41:221-9. 
Michel G, Rebholz CE, von der Weid NX, Bergstraesser E, Kuehni CE. Psychological 
distress in adult childhood cancer survivors: the Swiss Childhood Cancer Survivor 
Study. Journal of Clinical Oncology 2010; 28:1740-7. 
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Project 6 – Risk of cancer and long-term mortality in children treated with 
Growth hormone: Swiss participation in the EU FP7 project “SAGhE” 
 
 
Background: Since 1985 recombinant growth hormone (GH) has been available. 
Initially it was used to treat cases of primary severe growth hormone deficiency (GHD) 
but its use has since multiplied to include various indications where childhood short 
stature is not primarily due to deficient endogenous GH secretion, for instance Turner 
Syndrome, Prader-Willi Syndrome, children born short for gestational age (SGA), 
chronic renal failure and idiopathic short stature. Another important indication is 
childhood cancer. GHD is the most common endocrine late effect of cancer treatment in 
children, especially after brain tumours and cranial irradiation. Efficacy of GH in children 
with severe GHD is undisputed and short term safety during treatment is generally 
considered satisfactory. Data on efficacy for other indications, association with quality of 
life and long-term safety are scarce due to limited numbers of patients within individual 
countries. Several experimental studies have raised concerns with regards to cancer 
risk and long-term mortality. To overcome the problem of low numbers, an international 
consortium including investigators from eight different countries in addition to 
Switzerland was constituted to study “Safety and Appropriateness of Growth hormone 
treatments in Europe” (SAGhE).  
 
Objectives: We aim to establish a cohort of young adults treated with GH in childhood 
due to different diagnoses, and to describe the indications and frequency of GH used for 
children in Switzerland since 1985; to assess the long-term efficacy and quality of life in 
adulthood after GH-treatment in childhood; and to investigate the long-term safety of 
GH-treatment in childhood, in particular the risk of cancer and mortality during child- and 
adulthood. 
 
Methods: To identify all eligible patients, we will collect information from: a) patient lists 
of all paediatric endocrinology departments and practicing paediatric endocrinologists in 
Switzerland; b) databases: KIGS – Pfizer International Growth Database; databases of 
the SCCR, the Swiss Childhood Cancer Survivor Study and the Swiss Paediatric Renal 
Registry. Relevant data will be extracted from hospital records and registry databases. 
Assessment of quality of life will be done via questionnaire survey. The number of 
cancer diagnoses and mortality will be assessed by deterministic and probabilistic 
linkage of the databases with the cantonal cancer registries in Switzerland and with the 
mortality statistics of the Swiss Federal Statistical Office. For participants living in 
cantons not covered by a cancer registry, cancer outcomes will be assessed via 
questionnaire survey. 
The risk of cancer and mortality in the cohort will be compared to the risk in the general 
population by calculating standardized incidence rates and standardized mortality rates. 
For diagnoses with increased baseline risks (childhood cancer survivors, chronic renal 
failure), the risk in GH-treated patients will be compared to the risk in untreated patients 
with similar diagnoses. 
 
Rationale and significance: The project will describe the use of GH in Switzerland and 
analyse long-term safety in the frame of a high-quality international collaborative study. 
Results will be presented to the public, guidelines committees and health authorities and 
are likely to influence future recommendations for treatment with GH in children, 
particularly in children suffering from cancer. Furthermore, prospective data collection 
will be continued and will serve as a resource for future research. 
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Study Team 
 
Applicants: Mullis P. University Children Hospital, Inselspital Bern, Department for 
Paediatric Endocrinology, Diabetology and Metabolism; Kuehni CE, Bohlius J. Institute 
of Social and Preventive Medicine, University of Bern; Grotzer M. University Chlidren’s 
Hospital, Zurich; Clough-Gorr K. NICER, Institute of Social and Preventive Medicine, 
University of Zurich. 
Project team: Sommer G, Karabulut F, Kuehni CE. Institute of Social and Preventive 
Medicine, University of Bern; Mullis P. University children hospital, Inselspital Bern, 
Department for Paediatric Endocrinology, Diabetology and Metabolism. 
 
Funding: EU-FP7 call HEALTH-2007-3.1-5: Better use of medicines, Swiss Cancer 
League (Oncosuisse) 
 
Contact:  Grit Sommer (gsommer@ispm.unibe.ch) 
Claudia Kuehni (kuehni@ispm.unibe.ch) 
 
Publications: Expected for 2012 
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Project 7 – Childhood leukaemia and lymphoma: are incidence and survival 
in Switzerland associated with socio-economic status?  
 
 
The research project aims to investigate the association of socio-economic status (SES) 
with the risk of developing childhood leukaemia or childhood lymphoma, and to explore 
whether the association is varying with the operational definition of socio-economic 
status. 
 
Objectives: 1) To investigate the association of socio-economic status with the risk of 
developing childhood leukaemia or childhood lymphoma, and to explore whether the 
association is varying with the operational definition of socio-economic status. 2) To 
investigate the association of socio-economic status with the five-year survival rate for 
cases of childhood leukaemia or childhood lymphoma. 
 
Methods: The two main aims are addressed by a case-control study design (for the 
association between SES and the risk of disease) and by a prospective cohort study 
design of the included cases (for potential differentials in mortality and survival). The 
study includes all cases of childhood leukaemia or lymphoma registered in the SCCR, 
who were diagnosed between 1991 and 2006 and were recorded either in the 1990 or in 
the year 2000 census (approximately 700 leukaemia and 300 lymphoma cases). Having 
been recorded in one of the censuses is necessary to obtain relevant information on the 
SES of the child’s parents, i.e. profession and education. Other measures available from 
the census data include information on the living conditions, i.e. the number of rooms 
per person in the household and ownership of house or apartment. In addition, we use 
the recently developed Sotomo-Index, an area-based SES measure which is defined by 
the community in which a person lives (www.sotomo.geo.unizh.ch). To obtain the SES 
information from the census records we have developed and will use methodologically 
sound probabilistic record linkage procedures. For the case-control study we have 
selected for each case 10 control children from the two census rounds. We can thus 
include approximately 1000 cases and 10,000 control subjects in the case-control part 
of the study. Analysis is being performed by logistic regression and time-to-event 
analyses (life-table, Kaplan-Meier estimates and proportional hazards models). 
 
Rationale and significance: Childhood leukaemia and childhood lymphoma comprise 
about half of all cancer diagnoses in children. Therefore, assessing SES as a risk factor 
for this subgroup is of public health relevance. Using the population-based childhood 
cancer registry in this study will provide accurate measures of risk for developing 
childhood leukaemia or lymphoma. 
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Project 8 – An international case-control study on brain tumours in 
children and adolescents – CEFALO 
 
 
Background: It has been hypothesized that children could be more vulnerable to radio 
frequency electromagnetic field exposures from mobile telephones than adults, but no 
epidemiological studies of this potential association have been performed so far. The 
lack of knowledge causes conflicting recommendations from decision-makers, leading to 
anxiety and insecurity in the population. That is the reason why the WHO put a case-
control study on radio frequency electromagnetic fields and childhood brain tumours as 
a high priority on their 2006 research agenda. 
 
Objectives: The main goal of the study is to investigate whether the use of mobile 
telephones increases the risk of developing brain tumours for children or adolescents. In 
addition, our study will provide a comprehensive dataset to investigate other potential 
risk factors for childhood brain tumours. 
 
Study design: The questions are being investigated by means of an international case-
control study in Denmark, Norway, Sweden and Switzerland. Cases were identified 
through a combination of registry data and information from the wards treating the cases 
(e.g. Swiss Paediatric Oncology Group). All incident cases of brain tumour at age 7-19 
years between May 2004 and April 2008 were invited to participate. In total, the study 
includes 550 cases of brain tumours in all participating countries, of which 100 originate 
from Switzerland. For each case, two control persons have been randomly selected 
from the general population, matched on age, sex and geographic region. 
 
Exposure assessment: Information on the extent of exposure to radio frequency fields 
from mobile phones, and on other known and suspected risk factors for childhood brain 
tumours is obtained by means of computer assisted personal interviews conducted by 
an interviewer trained for this purpose. The interviews took place either at the hospital or 
at the study participant’s home. Objective information on the frequency and duration of 
mobile phone use is being obtained from mobile phone operators and from the 
information stored in the telephone that is in current use. 
 
Data analyses: The data are being analyzed using statistical methods for case-control 
studies, primarily via logistic regression models adjusted for potential confounders. In 
order to investigate potential gene-environment interactions, DNA from saliva samples is 
being extracted and analysed. Polymorphisms in genes that affect oxidative metabolism, 
detoxification of carcinogens, DNA stability and repair, or immune response, are 
candidates that might confer genetic susceptibility to brain tumours. 
 
Rational and significance: Since the 1990s there has been a steep increase in the 
ownership of mobile phones and the amount of their use throughout the world. This 
increase has raised concerns about their possible detrimental health effects. Due to the 
proximity of mobile phones to the head during calls, brain tumours have been the 
primary concern. Further, recent studies indicate that children have higher energy 
absorption than adults and thus may be more vulnerable to mobile phone RF radiation. 
The lack of knowledge leads to anxiety and insecurity in the population. The WHO and 
the National Academies (USA) have put a case-control study on childhood brain 
tumours as a high priority on their research agenda on radio frequency electromagnetic 
fields. If mobile phone use is associated with an increased brain tumour risk, this is of 
high public health importance. With the exposure prevalence now reaching almost 100% 
in many countries worldwide, even a moderate association would cause a considerable 
number of additional cases attributable to mobile phone usage. Up to date, no studies 
are available that have specifically addressed the possible association between mobile 
phones and the risk of brain tumours among children and adolescents. 
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5 Improvement of completeness and quality in 2009 - 
2010 
In a previous study comparing the cases registered in the SCCR with those registered in 
individual cantonal cancer registries for the years 1990 to 2004 we found that both the 
SCCR and the cantonal registries missed a certain proportion of cases only registered in 
one of the two databases.12 To detect and register these missed cases in both registries 
(SCCR and cantonal) it is necessary to compare the two datasets and exchange data at 
regular intervals.  
Collaboration with cantonal cancer registries 
With the 11 cantonal cancer registries the SCCR has recently agreed on a standardized 
procedure for the identification and exchange of patient records missed in each registry. 
The procedure respects different situations in different cantons, e.g. regulations on data 
protection. The aim of the data exchange is to improve the quality and completeness of 
the information collected in both registries for children and young adults diagnosed with 
cancer at age 0-20 years (<21 years). The general authorization of the Federal Expert 
Commission for Professional Secrecy in Medical Research allows these exchanges. 
The first data comparison was done retrospectively with all cases registered in each 
registry since data collection started. The comparison with data collected in the cantonal 
cancer registries of the cantons Fribourg, Geneva, Grisons & Glarus, Vaud, Valais, 
Neuchâtel and Zurich was completed by the end of 2010. A comparison with the 
remaining cantonal registries will be completed early in 2011.  
Collaboration with pathology laboratories 
In cantons without a cantonal cancer registry (e.g. Bern, Aargau, Thurgau) other 
sources of data need to be used to improve data quality and completeness in the 
SCCR. One way to find missed cases is to compare data with local pathology 
laboratories. In Bern, pathology laboratories were contacted and collaboration was 
established with the major laboratories (“Institute for Pathology” at the University of Bern 
and “Unilabs”).  
Collaboration with pathology laboratories may also help to detect second tumours, 
which will be identified for different research projects.  
Collaboration with the Swiss Federal Statistical Office 
Collaboration was also established with the FSO. The FSO provides anonymised data 
on mortality in the population aged 0-25 years in Switzerland. This allows the SCCR to 
check and complete dates of death in its database and therefore to calculate survival 
time. Rarely, cases had only been diagnosed shortly before or just after death. 
Therefore this procedure allows the SCCR to register “death certificate only” cases 
(DCO).  
Since 2010 the FSO also provides anonymised data on the hospitalisation of cases with 
cancer diagnoses in Swiss hospitals. According to ICD-10 diagnostic codes and the age 
at diagnosis, we are able to find hospitals other than SPOG centres which also treated 
childhood cancer cases. This allows the SCCR to contact the corresponding hospital 
and register these cases. In the past not all childhood cancer cases were treated in a 
specialized cancer care unit and still today many adolescents are treated in adult 
oncology centres.  
                                               
12 Adam M, von der Weid NX, Michel G, Zwahlen M, Lutz JM, Probst-Hensch N, Niggli F, Kuehni CE. Access to 
specialized pediatric cancer care in Switzerland. Pediatric Blood & Cancer 2010; 54:721-7. 
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6 Publications  
All articles published using SCCR data from January 2006 – April 2011 are reported 
below. Additional publications related to the SCCR or SPOG can be found on the SCCR 
and SPOG websites: www.childhoodcancerregistry.ch and www.spog.ch. 
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7 Abbreviations 
AML Acute Myeloid Leukaemia 
ALL Acute Lymphoblastic Leukaemia 
BMT Bone Marrow Transplantation 
CANUPIS Childhood Cancer and Nuclear Power Plants in Switzerland 
CCFU Childhood Cancer Follow-up study 
CHUV Centre Hospitalier Universitaire Vaudois 
CNS Central Nervous System 
DNA Deoxyribonucleic Acid 
EBMT The European Group for Blood and Marrow Transplantation 
ENCR European Network of Cancer Registries 
FOPH Federal Office of Public Health 
FSO Federal Statistical Office 
GCCR German Childhood Cancer Registry, Mainz, Germany 
GH Growth Hormone 
GHD Growth Hormone Deficiency 
GIS Geographic Information System 
HUG Hôpitaux Universitaires de Genève 
HRQoL Health Related Quality of Life 
IACR International Association of Cancer Registries 
IARC International Association of Research in Cancer 
ICCC-3 International Classification of Childhood Cancer, Third revision 
ICD-10 International Statistical Classification of Diseases and Related Health 
Problems, Tenth revision 
ICD-O-3 International Statistical Classification of Diseases for Oncology, Third 
edition 
ISPM Institute of Social and Preventive Medicine, Bern 
LCH Langerhans Cell Histiocytosis 
NBR National Birth Registry 
NICER National Institute for Cancer Epidemiology and Registration, Zurich 
NPP Nuclear Power Plants 
NRCT National Registry of Childhood Tumours, Oxford, England 
PanCare Pan-European Network for Care of Survivors after Childhood and 
Adolescent Cancers 
PNET Primitive Neuroectodermal Tumour 
RF Radio Frequency 
SAGhE Safety and Appropriateness of Growth Hormone Treatment in Europe 
SCCR Swiss Childhood Cancer Registry 
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Abbreviations - continued 
 
SCCSS Swiss Childhood Cancer Survivor Study 
SES Socio-Economic Status 
SGA Short for Gestational Age 
SNC Swiss National Cohort 
SPOG Swiss Paediatric Oncology Group 
SurFup PanCare Survivor Care and Follow-up Study 
STS Soft Tissue Sarcoma 
UKBB Universitätskinderspital beider Basel 
WHO World Health Organization 
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8 Appendix: Classification of cancer diagnoses  
International Classification of Childhood Cancer - ICCC-3 
The third edition of the International Classification of Childhood Cancer (ICCC-3) represents 
the standard for presentation of international data on childhood cancer incidence and 
survival.13 It applies the rules, nomenclature and codes (morphology, topography and 
behaviour) of the ICD-O-3. Furthermore, ICCC-3 categories are defined in conformity with 
international classifications of the pathology and genetics of childhood cancers. In the ICCC-
3, three hierarchical levels have been developed: level one consists of 12 main diagnostic 
groups and level two of 47 diagnostic subgroups. These two levels of the ICCC-3 allow 
standardised comparison of the broad categories of childhood tumours. Level three, an 
optional “extended” classification, comprises two to eleven divisions of selected diagnostic 
subgroups. The division of some diagnostic subgroups, e.g. leukaemias and Non-Hodgkin 
lymphomas, reflects the availability of detailed cytogenetic or molecular information that 
permits homogeneous groups of tumours to be distinguished within them and thus allows 
their separate study. Most childhood cancer registries only use level one and two. Only 
malignant neoplasms are classified in ICCC-3, with the exception of non-malignant 
intracranial and intraspinal tumours. Tumours known to occur only rarely in young patients 
are also included in ICCC-3. The ICCC-3 is used if data are compared with other childhood 
cancer registries. 
International Statistical Classification of Diseases for Oncology - ICD-O-3 
The third edition of the International Statistical Classification of Diseases for Oncology (ICD-
O-3)14 has been developed by a working group hosted by the International Association of 
Research in Cancer (IARC) and WHO. The morphology code for neoplasm has been 
revised, especially for lymphomas and leukaemias. In contrast to the ICD-10 classification, 
ICD-O-3 uses only one set of four characters for topography (based on the malignant 
neoplasm section of ICD-10). The topography code remains the same for all neoplasms of 
that site. The behaviour code is incorporated as the fifth digit in the morphology field. It 
identifies whether the tumour is malignant, benign, of uncertain or unknown behaviour, in 
situ, presumed to be primary or secondary. ICD-O-3 is used to compare data with general 
cancer registries. 
International Statistical Classification of Diseases and Related Health Problems - ICD-
10 
The International Statistical Classification of Diseases and Related Health Problems (ICD)15 
permits the systematic recording, analysis, interpretation and comparison of mortality and 
morbidity data collected in different regions and at different time periods. The ICD has 
become the international standard diagnostic classification for all general epidemiological 
purposes. The ICD-10 classification comprises three volumes: Volume 1 contains the main 
classifications; Volume 2 provides guidance for users of the ICD; and Volume 3 is the 
alphabetical index to the classification. Classification is divided into 21 chapters. The first 
character of the ICD code is a letter. Each letter is associated with a particular chapter, e.g. 
the letter D is used in both chapter II “Neoplasms” and chapter III “Diseases of the blood and 
blood-forming organs and certain disorders involving the immune mechanism”. The 
topography code in Volume 3 describes the site and the behaviour of the neoplasm: 
malignant, secondary or metastatic, in situ, benign or of unknown behaviour. The 
morphology codes listed in Volume 1 are the same as those used in the special adaptation 
of the ICD for oncology, the ICD-O (-2). 
 
                                               
13 Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third 
Edition. Cancer 2005; 103:1457-67. 
14 World Health Organization. International Statistical Classification of Diseases for Oncology - Third Edition (ICD-O-
3). Geneva: World Health Organization; 2000. 
15 World Health Organization. International Statistical Classification of Diseases and Related Health Problems - 
Tenth Revision. Geneva: World Health Organization; 1993. 
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